サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1420997

ギランバレー症候群市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年

Guillain-Barre Syndrome Market (Therapeutics: Intravenous Immunoglobulin, Plasma Exchange, and Others; and Route of Administration: Oral and Parenteral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 194 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ギランバレー症候群市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年
出版日: 2023年12月22日
発行: Transparency Market Research
ページ情報: 英文 194 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ギランバレー症候群市場 - レポートの範囲

世界のギランバレー症候群市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、世界のギランバレー症候群の収益を提供します。 2023年を基準年、2031年を予測年とみなす、2017年から2031年の期間のバレー症候群市場。レポートは、2023年から2031年までの世界のギランバレー症候群市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、ギランバレー症候群市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 5億9,130万米ドル
2031年の市場価値 8億9,020万米ドル
CAGR 4.7%

このレポートは、世界のギランバレー症候群市場の競合情勢を詳しく掘り下げています。世界のギランバレー症候群市場で活動している主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界のギランバレー症候群市場の企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017年～2031年

第5章 重要な洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主な合併と買収
  • COVID-19感染症のパンデミックが業界に与える影響

第6章 世界市場の分析と予測：治療別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：治療別、2017年～2031年
    • 免疫グロブリンの静注
    • 血漿交換
    • その他
  • 市場魅力分析：治療別

第7章 世界市場の分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：投与経路別、2017年～2031年
    • 経口
    • 非経口
  • 市場魅力度分析：投与経路別

第8章 世界市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：流通チャネル別、2017年～2031年
    • 病院
    • 薬局
    • 小売薬局
    • その他
  • 市場魅力度分析：流通チャネル別

第9章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017年～2031年
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 南米市場の分析と予測

第14章 中東・アフリカ市場の分析と予測

第15章 競合情勢

  • 市場企業 - 競争マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Grifols SA
    • CSL Behring LLC
    • Shire plc
    • Octapharma AG
    • Nihon Pharmaceutical Co.,Ltd
    • Akari Therapeutics, PLC
    • Biotest AG
    • Kedrion SpA
図表

List of Tables

  • Table 01: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
  • Table 02: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
  • Table 07: North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 08: North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
  • Table 11: Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 12: Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
  • Table 15: Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16: Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: South America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: South America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
  • Table 19: South America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: South America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017-2031
  • Table 23: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Guillain-Barre Syndrome Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
  • Figure 02: Global Guillain-Barre Syndrome Market Revenue (US$ Mn), by Therapeutics, 2022
  • Figure 03: Global Guillain-Barre Syndrome Market Value Share, by Therapeutics, 2022
  • Figure 04: Global Guillain-Barre Syndrome Market Revenue (US$ Mn), by Route of Administration, 2022
  • Figure 05: Global Guillain-Barre Syndrome Market Value Share, by Route of Administration, 2022
  • Figure 06: Global Guillain-Barre Syndrome Market Revenue (US$ Mn), by Distribution Channel, 2022
  • Figure 07: Global Guillain-Barre Syndrome Market Value Share, by Distribution Channel, 2022
  • Figure 08: Global Guillain-Barre Syndrome Market Value Share, by Region, 2022
  • Figure 09: Global Guillain-Barre Syndrome Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 10: Global Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
  • Figure 11: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023-2031
  • Figure 12: Global Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 13: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 14: Global Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 15: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 16: Global Guillain-Barre Syndrome Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 17: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 18: North America Guillain-Barre Syndrome Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Guillain-Barre Syndrome Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 21: North America Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
  • Figure 22: North America Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 23: North America Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 24: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023-2031
  • Figure 25: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 26: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 27: Europe Guillain-Barre Syndrome Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 28: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 30: Europe Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
  • Figure 31: Europe Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 32: Europe Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023-2031
  • Figure 34: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 35: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 36: Asia Pacific Guillain-Barre Syndrome Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 37: Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 39: Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
  • Figure 40: Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 41: Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 42: Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023-2031
  • Figure 43: Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 44: Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 45: South America Guillain-Barre Syndrome Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 46: South America Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: South America Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 48: South America Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
  • Figure 49: South America Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 50: South America Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 51: South America Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023-2031
  • Figure 52: South America Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 53: South America Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 54: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 55: Middle East & Africa Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 57: Middle East & Africa Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
  • Figure 58: Middle East & Africa Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 59: Middle East & Africa Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 60: Middle East & Africa Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023-2031
  • Figure 61: Middle East & Africa Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 62: Middle East & Africa Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023-2031
目次
Product Code: TMRGL26765

Guillain-Barre Syndrome Market - Scope of Report

TMR's report on the global Guillain-Barre Syndrome market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Guillain-Barre Syndrome market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Guillain-Barre Syndrome market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Guillain-Barre Syndrome market.

Market Snapshot
Market Value in 2023US$ 591.3 Mn
Market Value in 2031US$ 890.2 Mn
CAGR4.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Guillain-Barre Syndrome market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Guillain-Barre Syndrome market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Guillain-Barre Syndrome market.

The report delves into the competitive landscape of the global Guillain-Barre Syndrome market. Key players operating in the global Guillain-Barre Syndrome market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Guillain-Barre Syndrome market profiled in this report.

Key Questions Answered in Global Guillain-Barre Syndrome Market Report:

  • What is the sales/revenue generated by Guillain-Barre Syndrome across all regions during the forecast period?
  • What are the opportunities in the global Guillain-Barre Syndrome market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Guillain-Barre Syndrome Market - Research Objectives and Research Approach

The comprehensive report on the global Guillain-Barre Syndrome market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Guillain-Barre Syndrome market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Guillain-Barre Syndrome market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Guillain-Barre Syndrome Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Guillain-Barre Syndrome Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Therapeutics

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Therapeutics, 2017-2031
    • 6.3.1. Intravenous Immunoglobulin
    • 6.3.2. Plasma Exchange
    • 6.3.3. Others
  • 6.4. Market Attractiveness Analysis, by Therapeutics

7. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospitals
    • 8.3.2. Pharmacies
    • 8.3.3. Retail Pharmacies
    • 8.3.4. Others
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. South America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Guillain-Barre Syndrome Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Therapeutics, 2017-2031
    • 10.3.1. Intravenous Immunoglobulin
    • 10.3.2. Plasma Exchange
    • 10.3.3. Others
  • 10.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.4.1. Oral
    • 10.4.2. Parenteral
  • 10.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.5.1. Hospitals
    • 10.5.2. Pharmacies
    • 10.5.3. Retail Pharmacies
    • 10.5.4. Others
  • 10.6. Market Value Forecast, by Country, 2017-2031
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Therapeutics
    • 10.7.2. By Route of Administration
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country

11. Europe Guillain-Barre Syndrome Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Therapeutics, 2017-2031
    • 11.3.1. Intravenous Immunoglobulin
    • 11.3.2. Plasma Exchange
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.4.1. Oral
    • 11.4.2. Parenteral
  • 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.5.1. Hospitals
    • 11.5.2. Pharmacies
    • 11.5.3. Retail Pharmacies
    • 11.5.4. Others
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Therapeutics
    • 11.7.2. By Route of Administration
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Guillain-Barre Syndrome Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Therapeutics, 2017-2031
    • 12.3.1. Intravenous Immunoglobulin
    • 12.3.2. Plasma Exchange
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.4.1. Oral
    • 12.4.2. Parenteral
  • 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.5.1. Hospitals
    • 12.5.2. Pharmacies
    • 12.5.3. Retail Pharmacies
    • 12.5.4. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Therapeutics
    • 12.7.2. By Route of Administration
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Country/Sub-region

13. South America Guillain-Barre Syndrome Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Therapeutics, 2017-2031
    • 13.3.1. Intravenous Immunoglobulin
    • 13.3.2. Plasma Exchange
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.4.1. Oral
    • 13.4.2. Parenteral
  • 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.5.1. Hospitals
    • 13.5.2. Pharmacies
    • 13.5.3. Retail Pharmacies
    • 13.5.4. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of South America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Therapeutics
    • 13.7.2. By Route of Administration
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Guillain-Barre Syndrome Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Therapeutics, 2017-2031
    • 14.3.1. Intravenous Immunoglobulin
    • 14.3.2. Plasma Exchange
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.4.1. Oral
    • 14.4.2. Parenteral
  • 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.5.1. Hospitals
    • 14.5.2. Pharmacies
    • 14.5.3. Retail Pharmacies
    • 14.5.4. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Therapeutics
    • 14.7.2. By Route of Administration
    • 14.7.3. By Distribution Channel
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Grifols S.A
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. CSL Behring LLC
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Shire plc
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Octapharma AG
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Nihon Pharmaceutical Co.,Ltd
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Akari Therapeutics, PLC
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. China Biological Products Holdings,Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Biotest AG
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Kedrion S.p.A
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview